CECILIA EBOT: Open Payments
NPI 1609571942 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$697 in 29 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $409 · 2025 $697
Food & beverage: $697
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 6 | $129 |
| ABBVIE INC. | 4 | $95 |
| E.R. Squibb & Sons, L.L.C. | 4 | $85 |
| Lundbeck LLC | 3 | $74 |
| Indivior Inc. | 2 | $68 |
| Janssen Pharmaceuticals, Inc | 1 | $58 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: VRAYLAR, COBENFY, ARISTADA, SUBLOCADE, INVEGA SUSTENNA, ABILIFY MAINTENA, INGREZZA, LYBALVI.
Industry payments across MD — which companies pay providers there.
